<DOC>
	<DOCNO>NCT01353729</DOCNO>
	<brief_summary>Approximately 40 healthy subject enrol . Each subject participate study approximately 9 week . There four treatment sequence 5-7 day washout treatment . Subjects admit clinical unit Day-1 dosing period remain unit Day 2 . Each subject receive single dose four treatment Day 1 treatment period randomize fashion . Subjects discharge clinical research unit completion assessment Day 2 period return approximately 5-7 day later next dose period . Serial pharmacokinetic sample collect 24 hour follow treatment .</brief_summary>
	<brief_title>A Study Evaluate Effect Intravenous Zanamivir Cardiac Conduction Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Zanamivir</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . Male female 18 55 year age inclusive , time signing informed consent . A female subject eligible participate nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea childbearing potential agrees use one contraception method list protocol . Body weight great equal 50 kg men great equal 45 kg woman BMI within range 18.531.0 kg/m2 ( inclusive ) . AST , ALT , alkaline phosphatase bilirubin less equal 1.5xULN ( isolated bilirubin &gt; 1.5x upper limit normal ( ULN ) acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Capable give write informed consent , include agreement comply requirement restriction list consent form The subject positive prestudy drug/alcohol screen . A minimum list drug screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . History sensitivity study medication , component thereof , history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . A history sensitivity heparin heparininduced thrombocytopenia enrol . History regular alcohol consumption within 6 month study define average weekly intake &gt; 14 drinks/week men &gt; 7 drinks/week woman . Has history regular use tobacco nicotinecontaining product within 3 month prior screen . Pregnant female determine positive serum urine human chorionic gonadotrophin ( hCG ) test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subjects history cholecystectomy , inflammatory bowel disease pancreatitis exclude . Subjects active peptic ulcer disease history upper gastrointestinal bleed A creatinine clearance le 80mL/min determined CockcroftGault equation . History/evidence clinically significant pulmonary disease , renal hepatobiliary disease . Subjects history nephrolithiasis exclude . A positive prestudy Human immunodeficiency virus ( HIV ) antibody test , positive Hepatitis B surface antigen Hepatitis C antibody result within 3 month screen . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Subjects hemoglobin &lt; 11 g/dL . A single repeat allow eligibility determination . The subject 's systolic blood pressure outside range 90140mmHg , diastolic blood pressure outside range 4590mmHg heart rate outside range 45100bpm female subject 45100 bpm male subject . Exclusion criterion screen ECG ( single repeat allow eligibility determination ) per protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>12-lead ECG</keyword>
	<keyword>cardiac repolarization</keyword>
	<keyword>QTc</keyword>
	<keyword>influenza</keyword>
	<keyword>GR121167</keyword>
	<keyword>zanamivir</keyword>
</DOC>